Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

ADA

This page shows the latest ADA news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

Novo Nordisk to cut US insulin prices by up to 75% in January 2024

Around 8.4 million of the 37 million people in the US with diabetes use insulin, according to the American Diabetes Association (ADA). ... The American Diabetes Association (ADA) issued a statement in response to Novo Nordisk’s cuts, with chief

Latest news

More from news
Approximately 19 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Despite their limitations, available outcome scales, such as the Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), are sufficiently sensitive to capture clinically meaningful changes.

  • Assessing the risks in annuity pricing models Assessing the risks in annuity pricing models

    GlaxoSmithKline (GSK) launched its gene therapy STRIMVELIS, a one dose treatment for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), in Europe in 2016 with an outcomes-based annuity

  • The fight for affordable insulin The fight for affordable insulin

    The movement is also distancing itself from some of the big type 1 diabetes advocacy organisations, such as the American Diabetes Association (ADA) and the Juvenile Diabetes Foundation (JDF), which it

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    Ada is an artificial intelligence (AI) app that helps patients navigate quickly and accurately to the right health service and, ultimately, the right diagnosis. ... So far, Ada has performed eight million assessments around the globe, and every three

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    GSK’s Strimvelis for ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency) followed in 2016, and was a similar commercial failure.

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and impressive R&D pipeline to apply the approach

  • Cello Health boosts senior leadership team Cello Health boosts senior leadership team

    He previously served as managing director at Medicom International, an international healthcare publishing firm as well as ADA holdings and ICI Pharmaceuticals.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Innovative Trials

Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ of experience, Innovative Trials deploys...

Latest intelligence

Actinic keratosis – a common skin condition that can lead to skin cancer
PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...

Quick links